RESEARCH
THE MICHAEL J . FOX FOUNDATION 2023 YEAR IN REVIEW
Catalyzing a Robust Pipeline for Drug Development : What Do Better Therapeutics Look Like ?
This year ’ s biomarker and staging breakthroughs are already boosting the pipeline of novel therapeutics targeting PD ’ s underlying biology and symptoms . By making objective biological diagnosis and measurement of Parkinson ’ s progression possible , these new tools promise to make clinical trials smarter , better and faster . This supercharged pipeline promises more effective
Improved Trial Timeline
Current Trial Timeline
The Biomarker Impact : Smarter , Faster , Cheaper Trials
A new paradigm can compress the timeline for testing by at least a decade .
Preclinical
Preclinical
0 Years 5 Years 10 Years 1
Clinical
Clinical
16